Novo Nordisk A/S’s EPS Growth at a glance
Novo Nordisk A/S reports eps growth of 21.4% for Dec 2024. The prior period recorded 52.3% (Dec 2023). Year over year the metric moved −30.9 pts (−59.1%). The rolling three-period average stands at 30.6%. Data last refreshed Dec 7, 2025, 2:49 AM.
Latest reading
21.4% · Dec 2024
YoY movement
−30.9 pts (−59.1%)
Rolling average
30.6%
Current EPS Growth
21.4%
−30.9 pts
−59.1%
Rolling average
30.6%
Latest Value
21.4%
Dec 2024
YoY Change
−30.9 pts
Absolute
YoY Change %
−59.1%
Rate of change
3-Period Avg
30.6%
Smoothed
Narrative signal
Novo Nordisk A/S’s eps growth stands at 21.4% for Dec 2024. Year-over-year, the metric shifted by −30.9 pts, translating into a −59.1% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How eps growth shapes Novo Nordisk A/S's story
As of Dec 2024, Novo Nordisk A/S reports eps growth of 21.4%. Review EPS trajectory, compounding pace, and earnings momentum supported by trailing annual filings.
Understanding EPS momentum
Sustained positive EPS growth underpins long-term shareholder returns. Volatility often reflects cyclical businesses or share-count changes.
Check the drivers behind EPS
Analyze revenue growth, margin expansion, and buybacks to see which levers are powering EPS gains.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
84.7%
Operating Margin
44.2%
Net Profit Margin
34.8%
Return on Equity
70.4%
Return on Assets
21.7%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Novo Nordisk A/S (NVO) FAQs
Answers tailored to Novo Nordisk A/S’s eps growth profile using the latest Financial Modeling Prep data.
What is Novo Nordisk A/S's current eps growth?
As of Dec 2024, Novo Nordisk A/S reports eps growth of 21.4%. This reading reflects the latest filings and price data for NVO.
How is Novo Nordisk A/S's eps growth trending year over year?
Year-over-year, the figure shifts by −30.9 pts (−59.1%). Pair this context with revenue growth and free cash flow signals to gauge momentum for NVO.
Why does eps growth matter for Novo Nordisk A/S?
Earnings-per-share growth reveals how quickly per-share net income is expanding or contracting versus the prior year. For Novo Nordisk A/S, operating within Healthcare — Drug Manufacturers - General, tracking this metric helps benchmark management's execution against close competitors.
Is Novo Nordisk A/S's eps growth above its recent average?
Novo Nordisk A/S's rolling three-period average sits at 30.6%. Comparing the latest reading of 21.4% to that baseline highlights whether momentum is building or fading for NVO.
How frequently is Novo Nordisk A/S's eps growth refreshed?
Data for NVO was last refreshed on Dec 7, 2025, 2:49 AM and updates automatically every 24 hours, keeping your valuation inputs current.